Alzheimer’s disease (AD) is an aging-related and progressive neurodegenerative disease related with age. At
the time of clinical manifestation of dementia AD, significant irreversible brain damage is already present, rendering the
diagnosis of AD at early stages of the disease an urgent prerequisite for therapeutic treatment to halt, or at least slow, the
onset or progression of the disease progression. Recent numerous studies using the state-of-art neuroimaging techniques
that have identified AD-like structural and functional brain changes in elderly people who are cognitively within the normal
range or who have mild cognitive impairment (MCI), a prodromal stage of the disease are discussed. In this review,
we discussed various neuroimaging measures that are proving to have potential values as biomarkers of preclinical AD
pathology for the its early detection and prediction as well as serving as a clinical trial outcome measures with additional
validations.